a Objectives: Establishment of an in vitro model to evaluate rectal safety and the efficacy of microbicide candidates.
Introduction
At a global level, sexual intercourse remains the major route of HIV transmission, and increasingly women are being disproportionately affected by the pandemic [1] . In the developed world, men who have sex with men (MSM) remain an important risk group for HIV infection. Recent documented increases in sexually transmitted infections in MSM populations [2] suggest that HIV infection rates within this group are unlikely to From the a St George's, University of London, London, UK, the diminish in the near future. It is recognized that anal intercourse is the sexual activity with the highest probability of HIV transmission when practised between serodiscordant couples [3] . Traditionally, it has been assumed that anal intercourse is primarily an MSM sexual behaviour. However, there is increasing epidemiological evidence to suggest that anal intercourse occurs at a significant rate in heterosexual populations [4, 5] . In the absence of an effective HIV vaccine, there is a critical need to develop new prevention technologies, including microbicides that prevent both vaginal and rectal HIV-1 transmission.
The differential vulnerability of the colorectum to HIV infection is partly explained by the histological differences between the intestinal and vaginal mucosae. The vagina is lined by a stratified squamous epithelium, whereas the rectal mucosa has a single-cell columnar epithelium. In addition, the intestinal lamina propria contains an abundance of highly activated target cells for HIV infection [6] [7] [8] . These histological and immunological differences between the vaginal and rectal compartments have implications for microbicide development. Products that are safe in the vaginal compartment may be dangerous when applied to the rectum. As an example, nonoxynol-9 is relatively well tolerated in the vagina when used infrequently [9] , but showed dramatic epithelial damage when a single dose was applied to the rectum [10, 11] . It is also conceivable that a product able to demonstrate efficacy vaginally may not protect when used rectally. This differential activity could be attributable to factors such as the increased surface area of the colorectum that would need to be protected, and the large population of susceptible cells present within the gastrointestinal mucosa. Given the heterogeneity of sexual practices seen in MSM and heterosexual individuals, it must be assumed that microbicides will be used for both anal and vaginal intercourse. As a consequence, it is necessary to develop algorithms for testing candidate microbicides for both compartments.
A preclinical safety and efficacy evaluation of rectal microbicides has not been standardized, and there is no equivalent of the rabbit vaginal irritation model used to evaluate vaginal microbicides. However, products have been evaluated in murine [12] , feline [13] , and macaque [14] [15] [16] models. These models can provide important data, but they are not suitable for the high throughput screening needed to evaluate the growing number of candidate microbicides. Cervicovaginal explant models have been used to study HIV pathogenesis [17] [18] [19] , and to screen candidate microbicides [17] [18] [19] [20] [21] . Similar models are required for rectal studies. Rectal tissue can be harvested from surgical resection specimens or collected using endoscopic biopsy techniques. Endoscopy provides the ability to collect tissue from a specific region of the intestine, but the quantity of tissue is limited to approximately 20 biopsies per subject. However, a greater number of intestinal explants (50-100) can be produced from intestinal resection specimens providing greater experimental flexibility.
In this paper, we describe our initial experience with the use of intestinal explants derived from both endoscopy and surgical resection specimens. We demonstrate that it is possible to infect intestinal explants productively and to use this ex-vivo model to screen microbicides for efficacy against HIV-1.
Materials and methods
Patients and tissue Surgical resection specimens of intestinal tissue were collected at St George's Hospital, London, UK, and endoscopic biopsies at UCLA Medical Center, Los Angeles, USA. All tissues were collected under protocols approved by the local internal review boards or ethics committees. All patients/subjects signed informed consent forms.
Endoscopic biopsies
Rectosigmoid biopsies were collected using a flexible sigmoidoscope, as previously reported [8] . Biopsy specimens were collected at 10 and 30 cm from the anal verge. Specimens were immediately placed into culture medium and maintained at room temperature until explant preparation, generally within one hour of sample collection.
Surgical tissue explants
Colorectal tissue was obtained from patients undergoing elective surgery. Indications for resection included rectocele repair and colectomy for colorectal cancer. Resection specimens were transported to the processing laboratory within 2 h of collection. On arrival, muscle was stripped from the resected tissue, which was then cut into 2-3 mm 3 explants comprising both epithelial and muscularis mucosae.
Cell phenotype studies
Mucosal mononuclear cells (MMC) were isolated from tissue biopsies by collagenase type II digestion, as previously described [22] . Collagenase treatment was shown not to affect cell surface markers [8, 22] . Lymphocyte subsets in whole blood and MMC preparations were quantified by Trucount (Becton Dickinson Immunocytometry Systems, California, USA) according to the manufacturer's instructions. Briefly, 50 ml whole blood or 50-100 ml MMC single-cell suspensions were added to each of the two tubes of MultiTest reagent containing either CD3-fluorescein isothiocyanate (FITC)/CD8-phycoerythrin (PE)/CD45-peridinin chlorophyll protein (PerCP)/CD4-allophycocyanin (APC) or CD3FITC/ CD16þCD56-PE/CD45-PerCP/CD19 APC. Red blood cells were lysed using 450 ml of FACS lysing solution (Becton Dickinson Immunocytometry Systems). Samples were analysed on a FACSCalibur (Becton Dickinson Immunocytometry Systems) using CellQuest software. Lymphocyte numbers were determined by gating on CD45-positive cells and confirmed by backgating to determine forward and side scatter profiles. For the determination of absolute cell counts, cell staining was performed in TruCount tubes containing a fixed number of lyophilized fluorescent beads. Absolute numbers (cells/ml) of CD45þCD3þCD4þ, CD45 þCD3þCD8þ, CD45þCD3-CD16þCD56þ, and CD45þCD3-CD19þ lymphocytes were quantified by dividing the number of positive cellular events by the number of bead events and multiplying the result by the bead concentration. Monoclonal antibodies included CD4 and HLA-DR-FITC, CD38 and CCR5-PE, CD8 and CD45-PerCP (Becton Dickinson Immunocytometry Systems), CD4 and CXCR4-APC (Pharmingen, California, USA). Whole blood and isolated MMC were stained for 20 min in the dark at room temperature, lysed with ammonium chloride (2Â for whole blood, 1Â for MMC), and washed with staining buffer (phosphatebuffered saline/1% fetal calf serum). Initial gating on isolated MMC was performed using side scatter and CD45 fluorescence followed by forward and side scatter gating.
Explant culture
Preliminary experiments were undertaken to optimize explant culture conditions, including: the choice of culture medium, the use of growth hormones, incubation parameters (temperature, gaseous environment), and explant support (data not shown). The optimized parameters used in subsequent experiments were: culture in Dulbecco's modified Eagle medium supplemented with L-glutamine (2 mmol), penicillin (100 U/ml), streptomycin (100 mg/ml) and gentamicin (50 mg/ml) in a 378C humidified atmosphere containing 5% carbon dioxide. To help maintain tissue structure, explants were cultured in pairs, with the epithelium uppermost, supported on presoaked gelfoam rafts (1 cm 2 , 7 mm thick; Pharmacia and Upjohn, Michigan, USA) at the air-media interface in 24-well plates containing 300 ml media. Explants were fed every 3-4 days with 200 ml media exchange.
Explant infection
HIV-1 SF162 and BaL used for these experiments were cultured in phytohemagglutinin-stimulated peripheral blood mononuclear cells. Cell-free viral stock was passed To help maintain tissue structure, colorectal tissue biopsy explants were cultured in pairs, with the epithelium uppermost, supported on pre-soaked gelfoam rafts at the air-media interface (a). Explants were fed every 3-4 days and cultured for up to 10 days with 50% media feeds every 3-4 days. Tissues were embedded in paraffin to be sectioned (7 micron) and stained with hematoxylin and eosin. Tissue morphology was through a 0.2 mm pore-size filter. Infection was monitored by viral p24 antigen (HIV-1 p24 enzymelinked immunosorbent assay; ELISA, AIDS Vaccine Program, National Cancer Institute, Frederick, Maryland, USA, carried out according to the manufacturer's protocol) or reverse transcriptase [23] .
Assessment of viral kinetics Tissue biopsies were infected through the application of 3 ml clarified viral stock on top of each biopsy (30Â TCID 50 , 0.5 ng p24) while supported on gelfoam rafts. After overnight incubation, biopsies were washed three times and placed on fresh gelfoam rafts for the remainder of the culture period. Explants were fed (50% media exchange) every 3-4 days, and assessed for viral replication over 10-12 days by p24 ELISA and HIV-1 RNA copy number.
Screening of candidate microbicides
Compounds used in this study were PRO2000 (Indevus Pharmaceuticals, Massachusetts, USA), dextrin sulphate (ML Laboratories, UK), PMPA (Gilead Sciences, USA), UC-781 (Biosyn Inc., Pennsylvania, USA) and TMC-120 (Tibotec, Belgium). All compounds were used at nontoxic concentrations. Compounds were diluted into culture media and used to make a 10-fold dilution series. Submerged explants were treated with media or compound (100 ml-2Â final concentration) for one hour before exposure to HIV-1BaL (100 ml, 10 3 -10 4 TCID 50 ) for 2 h in the presence of test compound. Control and compound-treated tissues were washed (Â6 in phosphatebuffered saline) to remove virus and compound, and explants were cultured on fresh gelfoam rafts as described, in the absence of compound. Cultures were assessed for viral replication after 10-12 days by p24 content of culture supernatants and HIV-1 proviral content of tissue.
Monitoring viral infection
Cultures were assessed for viral replication by: (i) p24 antigen content of culture supernatants: HIV-1 p24 ELISA; (ii) Proviral DNA (long-term repeat) content of tissue: assessed by multiplex quantitative real-time polymerase chain reaction (PCR; ABI Prism; Applied Biosystems, Foster City, California, USA) for HIV-1 DNA (long-term repeat) and (-actin as previously described [17] . To control for non-specific background binding or amplification, or a seropositive donor, controls included untreated tissue (no exposure to virus or compound), and tissue exposed to heat-inactivated (30 min, 568C) virus. Samples treated with PRO2000 had previously been shown to interfere with PCR, thus DNA samples were purified using Qiagen DNA Mini kit columns (Qiagen, California, USA, as per manufacturer's instructions) to eradicate any contaminating compound; (iii) HIV-1-RNA copy number: RNA was isolated from culture supernatants using the QIAamp MinElute virus spin kit (Qiagen) as per the manufacturer's instructions. Briefly, 200 ml of pure or diluted (with 0.15 mol sodium chloride) culture supernatant was applied to the column and processed as per the manufacturer's instructions. RNA was eluted from the column in 100 ml molecular biology grade water. Complementary DNA was generated using the ABI cDNA kit as per manufacturer's instructions (Applied Biosystems). Fifty-microlitre reactions were completed with 10 ml purified RNA; 5 ml cDNA was then amplified in a 25 ml volume PCR reaction using a SYBR green PCR mix containing 300 nmol of each forward and reverse primer for HIV-1SF162: forward:
0 . After AmpliTaq Gold activation (10 min, 958C), 45 PCR cycles (15 s 958C, 1 min 608C) were completed. A reference standard curve was obtained from serially diluting a known quantity of plasmid containing the target amplicon, as described [24] . The dissociation curve for each amplification was analysed to confirm the absence of non-specific PCR products.
Histology
To assess explant morphology during the course of the study, explants were harvested at days 0, 1, and 10 for histological examination. Formalin-fixed tissues were embedded in paraffin, sectioned (7 microns), and stained with hematoxylin and eosin.
Statistical analyses
All statistical analyses were determined using the Graphpad PRISM software (GraphPad Software, Inc., California, USA).
Results
Characterization of colorectal leukocyte phenotype and activation status To determine the utility of rectal and colonic tissue explants for HIV infection studies, we characterized the cell phenotype and activation status of leukocytes derived from rectal and colonic sites. Leukocytes were isolated from endoscopic biopsies taken at 10 cm (rectum) and 30 cm (sigmoid colon) from the anal margin. Using TruCount tubes and four-colour flow cytometry, the proportion of cells staining as CD4 or CD8 T cells (CD3), B cells (CD19), monocytes and natural killer cells was determined. There appeared to be little or no difference in any of the cell populations isolated from either the rectum or colon, and the proportion of each cell type appeared similar to those found in whole blood (Fig. 1a) . CD3þCD4þ T cells were further characterized for expression of HIV-1 co-receptors (CCR5 and CXCR4) and activation markers (CD38 and HLA-DR) (Fig. 1b,c) . Expression of CCR5 and HLA-DR was elevated in both colonic and rectal tissue when compared with blood. Some differences were also seen between the rectum and sigmoid colon, with colonic tissue showing slightly higher cell numbers expressing CCR5 and HLA-DR. The expression of CXCR4 and CD38 appeared to be more comparable between the blood and two intestinal sites. Using the mean fluorescent intensity of antibody binding to cell surface makers, it was also determined that the density of co-receptor expression varied between blood and both colorectal tissue sites. Not only did more CD4 cells express CCR5 in rectal and colonic mucosa, but these cells also appeared to express a greater density of CCR5 per cell (Fig. 1d) . The observed higher frequency of CCR5 target cells in rectal tissue expands our previous observation comparing the sigmoid colon to peripheral blood [8] , and suggests that the rectum and sigmoid colon would be equally susceptible to HIV-1 infection.
Colorectal explant culture
Having revealed a similar trend in terms of activation status and co-receptor expression in colonic and rectal biopsies, we evaluated culture conditions for colorectal explant culture. Culture variables including media composition, growth supplements, and modifications of both the gaseous and physical environment were evaluated (as outlined in the Methods section). Dulbecco's modified Eagle medium with L-glutamine and antibiotics (gentamicin, penicillin and streptomycin) in 5% carbon dioxide supported tissue viability (assessed by MTT assay) with no observed benefit on the addition of growth factors. Furthermore, the culture of tissue explants supported at the air-media interface on gelfoam rafts (Fig. 2a) further enhanced tissue viability (data not shown).
Although tissue remained viable for 10 days in culture, the structural architecture of colorectal explants was observed to degenerate with time ( Fig. 2b-d) . The ratio of CD4 to CD8 T cells was unchanged with the time in culture (Fig. 2e) . CCR5 expression reduced with time, both in terms of cell proportion and intensity (Fig. 2f,g ). The number of cells expressing CXCR4 remained constant but receptor intensity increased. Furthermore, the number of dual positive cells increased with time in culture (Fig. 2f) .
HIV infection of colorectal explants and preclinical evaluation of candidate microbicides
To determine the ex-vivo susceptibility of colorectal tissue biopsies to R5 HIV-1 infection, explants were exposed to HIV-1, and the kinetics of viral replication were assessed by the measurement of p24 and HIV-1 RNA in culture supernatants. Explant infection was readily demonstrated through the measurement of p24 and HIV-1 RNA. Maximal viral production was noted at day 10 ( Fig. 3) . Furthermore, there was a similar trend between levels of p24 and HIV-1 RNA.
Having established the ex-vivo susceptibility of colorectal explants to HIV-1 infection, we used this system to evaluate the efficacy of a number of potential candidate microbicide compounds against R5 HIV-1 infection of resected colorectal tissue explants. The candidates included: two polyanionic compounds (PRO2000 and dextrin sulphate), and three candidates from the reverse transcriptase inhibitor group [PMPA (nucleotide reverse transcriptase inhibitor; NRTI), UC-781 and TMC-120 (both non-nucleoside reverse transcriptase inhibitors; NNRTI)]. All compounds showed no evidence of toxicity, as assessed by the MTT viability assay at the highest dose tested (data not shown). This was in contrast to tissue treated with 1 mg/ml nonoxynol-9, which reduced viability to 69% after a 2-h treatment period.
PRO2000 was able to block infection of colorectal tissue completely at a concentration of 100 mg/ml, as assessed Day post viral exposure p24 (pg/ml)/ RNA copies/ml 6 8 10 12 14 Fig. 3 . Kinetics of HIV-1 replication in colorectal tissue biopsies. Colorectal tissue biopsies were exposed to HIV-1 SF162 overnight supported at the air-media interface on gelfoam rafts. Virus was then removed by extensive washing and explants were cultured supported on gelfoam rafts at the air-media interface. Explants were cultured for 12 days with 50% media feeds every 3-4 days. HIV-1 infection was determined by p24 antigen release into culture supernatant (*, solid line), and RNA copies per ml (*, dotted line). Data represent the mean AE SEM for three individual donors.
using real time quantitative PCR (Fig. 4a) . Furthermore, PRO2000 treatment gave over 99% protection against infection down to concentrations of 1 mg/ml. In contrast, dextrin sulphate provided a 99% protection at 1 mg/ml (Fig. 4b) . The nucleoside analogue PMPA demonstrated complete inhibition of HIV-1 infection at 10 mg/ml ( Fig. 5a ) with greater than 90% inhibition seen at concentrations as low as 0.1 mg/ml. The NNRTI, UC-781 and TMC-120, also demonstrated potent activity against HIV-1 infection. UC-781 was able to inhibit Fig. 4 . Activity of polyanionic compounds against HIV-1 infection of colorectal tissue explants. Paired colorectal tissue explants were exposed to HIV-1BaL for 2 h in the presence of test compound: (a) PRO2000; and (b) dextrin sulphate. Compound and virus was then removed by extensive washing and explants were cultured supported on gelfoam rafts at the air-media interface for 10 days with 50% media feeds every 3-4 days. HIV-1 infection was determined by polymerase chain reaction for the relative copy number of HIV-1 proviral DNA in proteinase K-digested tissue. Data represent the mean AE SEM for three individual donors in which each condition was tested in triplicate. RCN, Relative copy number. provirus formation totally at 3.3 mg/ml (Fig. 5b) , whereas TMC-120 demonstrated complete inhibition of infection at 0.33 mg/ml (Fig. 5c ).
Discussion
A number of microbicide candidates designed for vaginal application, including PRO2000, are currently being tested in phase III clinical trials. However, there is little knowledge as to the efficacy of these products if they were to be applied rectally. Furthermore, little work has been carried out to develop microbicides specifically for rectal use. There is thus an urgent need to develop suitable in vitro models to evaluate the use of such products for rectal application. In an attempt to mimic the in vivo situation more closely, we have developed an ex vivo model of colorectal tissue culture using modifications of established ex-vivo cervical [17] and lymphoid [25] explant culture systems.
A comparative study of cell populations present in the rectum and sigmoid colon was completed using biopsies taken from healthy volunteers to determine potential susceptibility to HIV-1 infection. As previously reported, vulnerable cell populations were seen in both colorectal tissue and blood. CD4 and CD8 T cells demonstrated higher levels of the HIV co-receptors CCR5 and CXCR4 when compared with blood [6] [7] [8] , with a high proportion of cells expressing both. In our study investigating the immunophenotypic differences between the rectum and sigmoid colon, there was a trend towards a slightly higher expression of CCR5 and HLA-DR, and greater CCR5 expression per cell from the sigmoid colon when compared with the rectum. The significance of these differences is unclear and is currently under further investigation in National Institutes of Health HPTN 056. However, these observations highlight the potential susceptibility of colorectal mucosa to HIV infection per se.
Having characterized the activation status and coreceptor expression levels of colorectal CD4 T cells at baseline, we determined favourable culture conditions for colorectal tissue explants. Explants derived from either colorectal biopsies or resected surgical tissue could be maintained in culture for 10-12 days. Although the tissue structure degenerated with time, CD4 : CD8 ratios remained constant, whereas CCR5 expression levels, although initially high, decreased during culture. Nevertheless, culture conditions were sufficient for productive infection by R5 strains of HIV-1. Because of the strong association of R5 isolates with mucosal transmission, we have focussed on evaluating the efficacy of microbicide against this viral phenotype. Additional experiments have demonstrated that colorectal explants are also susceptible to infection with X4 HIV-1 (data prepared for separate publication on co-infections). Such susceptibility to HIV-1 infection is not surprising given the efficiency of the transmission of HIV-1 across the colorectal mucosa and the profound replication of SIV and HIV-1 in gut-associated lymphoid tissue (GALT) irrespective of the route of transmission [26] . Furthermore, it validates the use of colorectal tissue for the preclinical assessment of potential microbicide candidates.
The ability of candidate microbicides to inhibit HIV-1 infection of colorectal tissue was evaluated with two classes of compounds. First-generation polyanion microbicide candidates PRO2000 and dextrin sulphate showed different degrees of activity. PRO2000 provided complete protection at a concentration representing a 1/50 dilution of the 0.5% formulated vaginal product and 99% protection at 1/5000 of the formulated dose. However, as this class of compound blocks viral attachment and fusion, such levels of compound would need to be maintained throughout the colorectum during exposure to virus (coitally dependent use). In contrast, dextrin sulphate only provided 99% protection at 1 mg/ml, equivalent to 1/40 of the vaginal formulation; it is possible that higher doses could have achieved 100% inhibition. Further studies would be required to determine the volume of product needed to obtain such localized concentrations. However, a requirement for larger gel volumes would probably reduce user acceptability. Importantly, these compounds demonstrated no toxicity to rectal mucosa at inhibitory concentrations, in contrast to nonoxynol-9.
Reverse transcriptase inhibitors PMPA (NRTI), UC-781 (NNRTI) and TMC-120 (NNRTI), considered as second-generation microbicide candidates, all showed potent activity against R5 HIV-1 infection. PMPA provided significant protection (90%) at concentrations 100 000-fold lower than the proposed vaginal formulation (1%). This greater dilution factor increases the chances of achieving such concentrations within target cells throughout the colorectum. Furthermore, the long half-life of this drug [27] suggests that target cells could remain resistant to infection for some time (hours) after application, which may lessen the requirement for maintaining coitally dependent drug concentrations. The NNRTI UC-781 and TMC-120 also showed potent activity. As both UC-781 and TMC-120 demonstrate prolonged activity against HIV-1 infection in cervical mucosal explants, providing protection up to 6 days post-drug treatment [28, 29] , it may be possible to develop formulations that could be applied rectally or vaginally in a coitally independent fashion. Ongoing studies are being carried out to investigate whether these drugs could provide prolonged protection in rectal explant cultures.
This study demonstrates that colorectal tissue explant culture is a useful tool for the preclinical evaluation of potential microbicides. This complements recent findings using an alternative model using phytohemagglutininactivated tissue [30] . The data presented here highlights major differences in the efficacy of a range of candidate microbicides, which may have important implications on their rational development as potential rectal microbicides. However, although these findings need to be confirmed in non-human primate challenge studies, the initial data suggest that, with appropriate formulation, rectally applied microbicides might provide protection from HIV-1 transmission. The development of such products is urgently needed to provide additional prevention options for both men and women at risk of infection through unprotected anal intercourse.
